Literature DB >> 24735697

Factors responsible for mother-to-child HIV transmission in Ontario, Canada, 1996-2008.

Dayu Lu, Juan Liu, Lindy Samson, Ari Bitnun, Sandra Seigel, Jason Brophy, Lynne Leonard, Robert S Remis1.   

Abstract

OBJECTIVE: Despite a high uptake of HIV screening and anti-retroviral prophylaxis in Ontario, several cases of mother-to-child (MTC) transmission occur every year. We wished to examine the modifiable factors responsible for MTC HIV transmission in Ontario, in particular HIV testing, antiretroviral prophylaxis and breast-feeding.
METHODS: Using the Ontario data from the Canadian Perinatal HIV Surveillance Program, we examined potential correlates of late maternal HIV diagnosis (i.e., diagnosed at or after delivery) among women delivering from 1996 to 2008. To better understand the factors responsible for MTC HIV transmission, we reviewed the medical charts of 35 HIV-infected infants born in Ontario.
RESULTS: Among the 645 HIV-infected mothers, 85 (13.2%) had late HIV diagnosis. The proportion with late HIV diagnosis significantly decreased during the study period, but did not differ by race/ethnicity group or maternal exposure category. With respect to the mothers of the 35 HIV-infected infants, 27 (77%) were diagnosed with HIV at or after delivery. The reasons no prenatal HIV test was performed were: not offered, offered but refused, no prenatal care, denied HIV testing history, and offered but not done. Reasons for no or incomplete antiretroviral  prophylaxis (ARP) among eight mothers diagnosed prior to or during pregnancy were: refused or non-compliant with ARP, and failed to inform care provider of HIV status.
CONCLUSIONS: Despite the recommendation for universal prenatal HIV counseling and voluntary testing adopted in Ontario, MTC transmission continued to occur, mostly due to late HIV diagnosis of the mother. Future work to reduce perinatal HIV infection should focus on enhancing timely HIV testing of pregnant women.

Entities:  

Keywords:  Canada; HIV; Ontario; antiretroviral prophylaxis (ARP); late diagnosis; mother-to-child transmission

Mesh:

Substances:

Year:  2014        PMID: 24735697      PMCID: PMC6972285     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  12 in total

1.  Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002-2006.

Authors:  Guthrie S Birkhead; Wendy P Pulver; Barbara L Warren; Sheila Hackel; Deborah Rodríguez; Lou Smith
Journal:  Obstet Gynecol       Date:  2010-06       Impact factor: 7.661

2.  HIV screening in pregnancy.

Authors:  Lisa Keenan-Lindsay; Mark H Yudin
Journal:  J Obstet Gynaecol Can       Date:  2006-12

3.  A national review of vertical HIV transmission.

Authors:  John C Forbes; Ariane M Alimenti; Joel Singer; Jason C Brophy; Ari Bitnun; Lindy M Samson; Deborah M Money; Terry C K Lee; Normand D Lapointe; Stanley E Read
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

Review 4.  Vertical transmission of HIV infection.

Authors:  M L Newell; C Peckham
Journal:  Acta Paediatr Suppl       Date:  1994-08

5.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

6.  Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

Authors: 
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

7.  Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission.

Authors:  Stephanie L Sansom; Denise J Jamieson; Paul G Farnham; Marc Bulterys; Mary Glenn Fowler
Journal:  Obstet Gynecol       Date:  2003-10       Impact factor: 7.661

8.  Rapid HIV-1 testing during labor: a multicenter study.

Authors:  Marc Bulterys; Denise J Jamieson; Mary Jo O'Sullivan; Mardge H Cohen; Robert Maupin; Steven Nesheim; Mayris P Webber; Russell Van Dyke; Jeffrey Wiener; Bernard M Branson
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

9.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

10.  Perinatal exposure to HIV among children born in Australia, 1982-2006.

Authors:  Ann M McDonald; Yvonne A Zurynski; Handan C Wand; Michelle L Giles; Elizabeth J Elliott; John B Ziegler; John M Kaldor
Journal:  Med J Aust       Date:  2009-04-20       Impact factor: 7.738

View more
  3 in total

Review 1.  Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?

Authors:  Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke
Journal:  ACS Chem Neurosci       Date:  2015-06-19       Impact factor: 4.418

2.  HIV prevalence and risk factors in infants born to HIV positive mothers, measured by dried blood spot real-time PCR assay in Tigray, Northern Ethiopia.

Authors:  Mulu Lemlem Desta; Muthupandian Saravanan; Haftamu Hilekiros; Atsebaha Gebrekidan Kahsay; Nesredin Futwi Mohamed; Alefech Addisu Gezahegn; Bruno S Lopes
Journal:  BMC Pediatr       Date:  2019-07-26       Impact factor: 2.125

3.  Knowledge, attitudes and practices of health personnel of maternities in the prevention of mother-to-child transmission of HIV in a sub-Saharan African region with high transmission rate: some solutions proposed.

Authors:  Elie Nkwabong; Romuald Meboulou Nguel; Nelly Kamgaing; Anne Sylvie Keddi Jippe
Journal:  BMC Pregnancy Childbirth       Date:  2018-06-14       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.